Paroxetine
- Generic Name
- Paroxetine
- Brand Names
- Paxil, Pexeva
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20FNO3
- CAS Number
- 61869-08-7
- Unique Ingredient Identifier
- 41VRH5220H
- Background
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this...
- Indication
Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the tr...
- Associated Conditions
- Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause
- Associated Therapies
- -
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2005-09-15
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 60
- Registration Number
- NCT00177567
- Locations
- 🇺🇸
University of Pittsubrgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Study Of Generalized Anxiety Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00135525
Seroquel in Bipolar Depression Versus SSRI
- Conditions
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 676
- Registration Number
- NCT00119652
- Locations
- 🇹🇷
Research Site, Manisa, Turkey
Serotonin and the Upper Airway in Obstructive Sleep Apnea
- Conditions
- First Posted Date
- 2004-12-31
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00100464
- Locations
- 🇺🇸
Malcolm Randall VA Medical Center, Gainesville, Florida, United States
Study of Antidepressants in Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2004-06-29
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 115
- Registration Number
- NCT00086190
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
- Conditions
- Interventions
- First Posted Date
- 2003-12-22
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Temple University
- Target Recruit Count
- 150
- Registration Number
- NCT00074802
- Locations
- 🇺🇸
Adult Anxiety Clinic of Temple University, Philadelphia, Pennsylvania, United States
🇺🇸New York State Psychiatric Institute Anxiety Disorders Clinic, New York, New York, United States
Treatment of Depression in Parkinson's Disease Trial
- Conditions
- Interventions
- First Posted Date
- 2003-06-13
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 52
- Registration Number
- NCT00062738
- Locations
- 🇺🇸
Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
- Conditions
- First Posted Date
- 2002-10-30
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 372
- Registration Number
- NCT00048204
Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression
- Conditions
- First Posted Date
- 2002-03-01
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 60
- Registration Number
- NCT00031317
- Locations
- 🇺🇸
National Institute of Mental Health (NIMH), Bethesda, Maryland, United States
Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients
- Conditions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018759
- Locations
- 🇺🇸
Edward Hines Jr. Hospital, Hines, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.